Lewes, DE -- (SBWIRE) -- 06/04/2015 -- The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous efforts by the JP government to promote increased use of generics (started in 2006 by launching various benefits for GE use at Pharmacy, hospital level) – now in 2014, Generic penetration of small molecules is changing the trend line and moving towards faster market penetration. While for biosimilars since their launch from 2009- various Japan specific factors has played role for each of them varied market penetration (Growth hormone, Erythropoietin, G-CSF).

2015 will be a litmus test for the next five years cumulative ¥400b biosimilar opportunity in Japan and will give clarity on the importance of "Made in Japan" (Filgrastim biosimilar competition amongst six players) and "Tested by Japan" (NK's Remicade biosimilar) factor for biosimilar penetration. It remains to be seen whether Japan will repeat the story of EU uptake (likes of Norway) for Remicade biosimilar or will follow any of the JP trend line of launched biosimilar (Growth hormone, Erythropoietin, G-CSF launched since 2009) for market penetration.

Approval of Remicade biosimilar with broader label (RA,UC,CD-PMS required for UC/CD) based on PhIII data of EU/Korean RA (Rheumatoid Arthritis) patients and PhI/IIb data in JP patients depict Japanese regulators to be less stringent than US and more or less similar to EU regulators for biosimilar approval requirements and provides ease on regulatory front for entering in Japan biosimilar market.

Consolidation activities are in place for biosimilar entry by a couple of big players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei), Global Multinationals (Pfizer, Sandoz) and some rising star JP local companies (Yoshindo, Gene Techno Science, Sanwa Kagaku). Recent learning suggests that expectations from partnering are not met at many places. This report provides a crisp summery on activities and plans of ~19 Japanese companies venturing in bio-similar space and ~6 multi-national companies that are going to play important role in the space. It also highlights how the consolidations activities are rapping up currently in biosimilar space, JP companies interest in hedging risk of biosimilar development by partnering with more than one company and where the opportunities are left unexplored for each RA and Oncology mAb.

In this report, along with JP regulatory/IP landscape for each mAb biosimilar opportunity, we attempt to evaluate the future competitive landscape in Japan, and assess the overall attractiveness of the same for market penetration (JP specific factor/Therapy specific factor). Considering NHI reimbursement bracket for each product, current market size of originator, expected no. of biosimilar players, JP biosimilar local companies key strength in specific therapy area/market (Hospital/GP/DP/DPC) etc.. - We try to identify the key determinates to succeed for each of the biosimilar opportunity in Japan.

Who should buy this report- Companies which are in biosimilar space in Japan + Companies want to enter in biosimilar space in Japan- They are

- EU biotech pharma companies developing mAb biosimilar
- US biotech Pharma companies developing mAb biosimilar
- South Korean biotech companies developing mAb biosimilar
- Chinese biotech companies developing mAb biosimilar
- Indian biotech companies developing mAb biosimilar for global market

EXECUTIVE SUMMARY
- 2015- A year of litmus test for complex mab biosimilar penetration in Japan??
- Upcoming next five year opportunities in biosimilar space in Japan
- Factors driving biosimilar penetration in Japan - What will weigh more? - JP specific factor or Therapy specific factor or else???

JP specific factor-
Use in DPC hospitals
Price difference for small molecule generic use vs. biologic- how big role it will play for biosimilar penetration
Reimbursement under high cost medical care Government benefit programme

Therapy Specific Factor-
Acute vs. Chronic/ Pediatric vs. Adult
Support therapy vs. treatment therapy
Physician experience of using class of therapy drugs….

Consolidation activities in biosimilar space in Japan-
Alliance done by JP innovator, JP Innovator+ Generic, JP generic companies –
Most of companies have cherry picked couple of biologics from full basket- and efforts ongoing for Tier 2 priorities
Some are still in dilemma for entering

Launch timeline and Our view on Each potential key opportunity in Biosimilar space in Japan based on
JP Market size, Expected no of players in biosimilar space in Japan, Innovator strategy in Japan, Re-examination period expiry
Key challenges for each biosimilar opportunities in Japan

For further information on this report, please visit- http://www.marketresearchreports.com/mp-advisors/new-phase-mab-biosimilar-knocks-door-biosimilar-opportunities-japan

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter